Pliant Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PLRX, updated each market day.
PLRX AI Sentiment
AI sees no strong directional signal for Pliant Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Pliant Therapeutics, Inc. Common Stock
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Sector
Exchange
Market Cap
$83,584,796
Cap Tier
Employees
49
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
June 3, 2020
Website
PLRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PLRX Volatility
Pliant Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
